RT Journal Article SR Electronic T1 Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.25.21254322 DO 10.1101/2021.03.25.21254322 A1 J. Ryan Bariola A1 Erin K. McCreary A1 Richard J. Wadas A1 Kevin E. Kip A1 Oscar C. Marroquin A1 Tami Minnier A1 Stephen Koscumb A1 Kevin Collins A1 Mark Schmidhofer A1 Judith A. Shovel A1 Mary Kay Wisniewski A1 Colleen Sullivan A1 Donald M. Yealy A1 David A Nace A1 David T. Huang A1 Ghady Haidar A1 Tina Khadem A1 Kelsey Linstrum A1 Christopher W. Seymour A1 Stephanie K. Montgomery A1 Derek C. Angus A1 Graham M. Snyder YR 2021 UL http://medrxiv.org/content/early/2021/03/30/2021.03.25.21254322.abstract AB Background Monoclonal antibody (mAb) treatment may prevent complications of COVID-19. We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and mortality, as well as Emergency Department (ED) visits without hospitalization, among outpatients at high risk of COVID-19 complications.Methods We compared patients receiving mAb to patients who met criteria but did not receive mAb from December 2020 through March 2021. The study population selection used propensity scores to match 1:1 by likelihood to receive mAb. The primary outcome was hospitalization or all-cause mortality within 28 days; the secondary outcome was hospitalization or ED visit without hospitalization within 28 days. Odds ratios (OR) calculation used logistic regression modeling including propensity score and mAb receipt predictors.Results The study population included 234 patients receiving mAb and 234 matched comparator patients not receiving mAb. Patients receiving mAb were less likely to experience hospitalization or mortality (OR 0.31, 95% confidence interval [95%CI] 0.17-0.56, p=0.00001) and hospitalization or ED visit without hospitalization (OR 0.50, 95%CI 0.43-0.83, p=0.007). The impact of mAb was more pronounced in prevention of hospitalization (among all age groups, OR 0.35, 95%CI 0.19-0.66, p=0.001) than mortality or ED visit without hospitalization, and most strongly associated with patients age 65 years and older (primary outcome OR 0.28, 95%CI 0.14-0.56, p=0.0003).Conclusions Bamlanivimab monotherapy was associated with reduction in the composite outcome of hospitalizations and mortality in patients with mild-moderate COVID-19. The benefit may be strongest in preventing hospitalization in patients ages 65 years or older.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the UPMC Quality Improvement Review Committee (Project ID 2882 and Project ID 3116).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data was used from electronic medical records as part of quality improvement and is not publicly available.